Basel Pharmaceuticals

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company headquartered in Basel, Switzerland, dedicated to developing innovative treatments for severe bacterial and fungal infections. The company's commercial portfolio includes the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole), both of which address high unmet medical needs in hospital settings. Basilea has established a robust global presence through strategic licensing agreements with partners such as Pfizer, Astellas Pharma, and Hikma Pharmaceuticals. While the company has historically explored oncology, it has recently refocused its strategy to become a leading player in the anti-infectives space, specifically targeting antimicrobial resistance. Basilea is publicly traded on the SIX Swiss Exchange and continues to expand its pipeline through both internal R&D and targeted acquisitions of clinical-stage assets.